Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Go back to Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine| (NASDAQ: VXRT) | Delayed: 0.32 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.32 | 52 Week High | $ | |||
| Open | $0.32 | 52 Week Low | $ | |||
| Day High | $0.32 | P/E | N/A | |||
| Day Low | $0.32 | EPS | $ | |||
| Volume | 503,141 | |||||
